CSPC Pharmaceutical Group Limited Share Price & Technical Analysis

CHJTF · $1.39 (+15.83%)

Healthcare / Drug Manufacturers - General

AI Score 85 · Strong Momentum

$1.39

+15.83%

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining caps

Price chart

Seasonality

May has 1 positive and 2 negative years (last 5 years shown)

0% return in May, 4% avg return in past 3 year May month.

21% return in 2026, 9% avg return in past 3 years.

Swipe sideways to see all months →

JanFebMarAprMayJunJulAugSepOctNovDecYr
2633%17%-29%0%0%21%
25-17%0%20%0%33%25%0%30%-15%-9%-10%0%57%
240%0%0%0%0%13%-11%-25%0%33%-12%-14%-17%
2320%-8%-9%0%-20%0%0%0%0%-12%29%-11%-12%
2230%0%-8%-17%-10%0%0%11%0%0%0%0%7%

Monthly return % by calendar month · historical pattern, not a forecast

AI snapshotScore 85/100

Strong Momentum · Uptrend · Exhausted

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent infection induced by chemotherapy; and Keaili for breast cancer. It also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, the company provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food products; and healthcare services. It has a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple therapies for obesity and type 2 diabetes. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

Full AI Q&A, portfolio tracking, and live alerts in the app.

Key metrics

Market cap

$15.85B

P/E ratio

27.8

52W high

$1.39

52W low

$0.81

Volume

1,000

Beta

0.80

Related stocks in Healthcare

Frequently asked questions

What is CSPC Pharmaceutical Group Limited share price today?
CSPC Pharmaceutical Group Limited (CHJTF) last traded around $1.39 on StockPro. Prices refresh every few minutes during market hours.
What technical signals does CHJTF have?
StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CHJTF. Download the app for real-time alerts.
How can I analyze CSPC Pharmaceutical Group Limited stock?
Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.

Explore more on StockPro